ReviewHead & face medicine2022

Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells-an in-vitro study.

Teresa F Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.